Get the Stockscreener App
37.80
0.00%
+0.00
After Hours:
37.80
Spyre Therapeutics Inc stock is currently priced at $37.80, with a 24-hour trading volume of 308.15K.
It has seen a +0.00% increased in the last 24 hours and a +10.17% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $37.78 pivot point. If it approaches the $38.72 resistance level, significant changes may occur.
Previous Close:
$37.80
Open:
$37.97
24h Volume:
308.15K
Market Cap:
$1.52B
Revenue:
$1.23M
Net Income/Loss:
$-338.79M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-99.91M
1W Performance:
+2.36%
1M Performance:
+10.17%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1D Range:
$36.94
$38.18
52W Range:
$10.42
$47.97
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Name
Spyre Therapeutics Inc
Sector
Industry
Phone
512 942 2935
Address
805 Las Cimas Parkway, Suite 100, Austin
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Dec-11-23 | Initiated | Guggenheim | Buy |
| Dec-11-23 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| Mar-21-19 | Initiated | JP Morgan | Overweight |
| Sep-04-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Apr-24-18 | Initiated | Evercore ISI | Outperform |
| Mar-14-18 | Reiterated | Needham | Buy |
View All
Spyre Therapeutics Inc Stock (SYRE) Latest News
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Analysts - MarketBeat
MarketBeat
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of “Buy” by Analysts - Defense World
Defense World
Spyre Therapeutics (SYRE) Price Target Increased by 5.00% to 42.84 - MSN
MSN
Spyre Therapeutics (SYRE) Price Target Increased by 5.00% to 42.84 - MSN
MSN
Spyre Therapeutics (NASDAQ:SYRE) Announces Quarterly Earnings Results - MarketBeat
MarketBeat
Spyre Therapeutics names Sandra Milligan to board By Investing.com - Investing.com
Investing.com
Spyre Therapeutics Inc Stock (SYRE) Financials Data
Spyre Therapeutics Inc (SYRE) Revenue 2024
SYRE reported a revenue (TTM) of $1.23 million for the quarter ending June 30, 2023, a -82.53% decline year-over-year.
Spyre Therapeutics Inc (SYRE) Net Income 2024
SYRE net income (TTM) was -$338.79 million for the quarter ending December 31, 2023, a -304.21% decrease year-over-year.
Spyre Therapeutics Inc (SYRE) Cash Flow 2024
SYRE recorded a free cash flow (TTM) of -$99.91 million for the quarter ending December 31, 2023, a -24.60% decrease year-over-year.
Spyre Therapeutics Inc (SYRE) Earnings per Share 2024
SYRE earnings per share (TTM) was -$72.84 for the quarter ending December 31, 2023, a -185.32% decline year-over-year.
About Spyre Therapeutics Inc
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
0.77%
1.20%
Cap:
|
Volume (24h):